April 11 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] expects net profit to exceed 310 million euro ($333 million) in 2024, it said on Thursday.
"Our target for 2024 is to reach 1.85 billion in sales for Krka Group products and services, with exports to account for 94% of total sales," the company said in a filing with the Ljubljana Stock Exchange.
In March, Krka said it recorded a consolidated net profit of 313.7 million euro in 2023, down 14%, whereas consolidated sales revenue increased by 5% to 1.806 billion euro.
Krka plans to invest more than 150 million euro primarily in expanding production and development facilities, infrastructure, and technological upgrades this year, while the total number of employees in Slovenia and abroad is projected to rise by 3%, the company said.
Over the next five years, the company plans to allocate 10% of revenue to research and development, with an average annual investment of 140 million euro, it noted.
($ = 0.9316 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here